Xamiol®Gel in BODY Psoriasis: A One-year Non-interventional Study

• Status: Completed
• Trial end date: 2018-02-15
• Target enrollment: 0
• Participant gender: All

Summary

This study aims to describe the patient population treated and the real-life patients' experiences with Xamiol®gel in the long term, up to 52 weeks management of body psoriasis vulgaris in Russia. The result will increase the knowledge on Xamiol®gel enabling dermatologists and patients to optimize its use in the long term management of psoriasis.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: LEO Pharma
• Treatments: Betamethasone; Betamethasone benzoate; Betamethasone sodium phosphate; Betamethasone Valerate; Betamethasone-17,21-dipropionate; Calcipotriene

Criteria

Inclusion Criteria:

• Psoriasis vulgaris on body

• Patients planned to receive topical treatment on the body with calcipotriol/betamethasone gel

• Written informed consent

Exclusion Criteria:

• No or very mild symptoms of psoriasis vulgaris on the body at study start

• Any on-going treatments at study start with topical steroids, salicylic acid or its combination

• Other topical treatment for body psoriasis

• Pregnancy or planned pregnancy within treatment period

• Contraindications according to prescribing information.